JP2016539929A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539929A5 JP2016539929A5 JP2016525990A JP2016525990A JP2016539929A5 JP 2016539929 A5 JP2016539929 A5 JP 2016539929A5 JP 2016525990 A JP2016525990 A JP 2016525990A JP 2016525990 A JP2016525990 A JP 2016525990A JP 2016539929 A5 JP2016539929 A5 JP 2016539929A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- aapc
- polyclonal
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 41
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 102100030704 Interleukin-21 Human genes 0.000 claims description 6
- 108010074108 interleukin-21 Proteins 0.000 claims description 6
- 229940127174 UCHT1 Drugs 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 3
- 230000000779 depleting effect Effects 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895626P | 2013-10-25 | 2013-10-25 | |
| US61/895,626 | 2013-10-25 | ||
| PCT/US2014/062191 WO2015061694A2 (en) | 2013-10-25 | 2014-10-24 | Polyclonal gamma delta t cells for immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539929A JP2016539929A (ja) | 2016-12-22 |
| JP2016539929A5 true JP2016539929A5 (enExample) | 2017-11-30 |
Family
ID=52993756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525990A Pending JP2016539929A (ja) | 2013-10-25 | 2014-10-24 | 免疫療法のためのポリクローナルγδＴ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9907820B2 (enExample) |
| EP (1) | EP3060059A4 (enExample) |
| JP (1) | JP2016539929A (enExample) |
| KR (1) | KR20160068960A (enExample) |
| CN (1) | CN105848484A (enExample) |
| AU (2) | AU2014339926B2 (enExample) |
| CA (1) | CA2926859A1 (enExample) |
| WO (1) | WO2015061694A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008521406A (ja) | 2004-11-24 | 2008-06-26 | フレッド ハッチンソン キャンサー リサーチ センター | 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法 |
| KR102238226B1 (ko) | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| EP3215534B1 (en) | 2014-11-05 | 2020-04-15 | Board of Regents, The University of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| US11135245B2 (en) | 2014-11-17 | 2021-10-05 | Adicet Bio, Inc. | Engineered γδ T-cells |
| US20220280564A1 (en) * | 2014-11-21 | 2022-09-08 | Immatics US, Inc. | Methods for expanding t cells for the treatment of cancer and related malignancies |
| WO2016138091A2 (en) | 2015-02-24 | 2016-09-01 | Board Of Regents, The University Of Texas System | Selection methods for genetically-modified t cells |
| CN107532174A (zh) | 2015-03-11 | 2018-01-02 | 得克萨斯州大学系统董事会 | 转座酶多肽及其用途 |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CA3021226A1 (en) * | 2015-05-11 | 2016-11-17 | University Health Network | Method for expansion of double negative regulatory t cells |
| WO2016183153A1 (en) * | 2015-05-12 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy |
| PT3307875T (pt) * | 2015-06-09 | 2022-03-21 | Lymphact Lymphocyte Activation Tech S A | Métodos para a produção de células t tcr gamma delta+ |
| JP6799895B2 (ja) * | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． | ＴＣＲγδ＋Ｔ細胞の生産方法 |
| KR20180041229A (ko) * | 2015-08-25 | 2018-04-23 | 유에이비 리서치 파운데이션 | 줄기 세포 이식을 위한 방법 |
| CN105112370B (zh) * | 2015-08-25 | 2019-02-05 | 杭州优善生物科技有限公司 | 一种体外刺激外周血γδT细胞高效增殖的方法及其应用 |
| KR20180042449A (ko) | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T 세포 수용체(tcr) 결합 항체 및 이의 용도 |
| CN105624107B (zh) * | 2015-09-21 | 2020-06-12 | 杭州优善生物科技有限公司 | 一种多种淋巴细胞亚群的扩增方法及其应用 |
| US11059879B2 (en) | 2015-10-27 | 2021-07-13 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor molecules and uses thereof |
| AU2016344779B2 (en) | 2015-10-30 | 2023-01-05 | Cancer Research Technology Limited | Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells |
| JP7210286B2 (ja) * | 2016-05-12 | 2023-01-23 | アディセット バイオ， インコーポレイテッド | γδＴ細胞集団の選択的増殖方法及びその組成物 |
| TWI788307B (zh) * | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| WO2018081784A1 (en) * | 2016-10-31 | 2018-05-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells for expanding immune cells for immunotherapy |
| WO2018147805A1 (en) * | 2017-02-08 | 2018-08-16 | Agency For Science, Technology And Research | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
| US20200297871A1 (en) * | 2017-09-15 | 2020-09-24 | King's College London | Compositions and methods for enhancing gamma delta t cells in the gut |
| CN107794269A (zh) * | 2017-09-30 | 2018-03-13 | 成都美杰赛尔生物科技有限公司 | 促进基因编辑t细胞活化及扩增的生物膜、制法及应用 |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| IL274640B1 (en) | 2017-11-15 | 2025-10-01 | Adicet Bio Inc | Methods for selective expansion of delta 3 gamma-delta T-cell populations and preparations thereof |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| BR112021005184A8 (pt) * | 2018-09-19 | 2022-08-16 | Lava Therapeutics B V | Imunoglobulina cd1d de dupla ação |
| EP3856206A1 (en) * | 2018-09-27 | 2021-08-04 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| EA202190926A1 (ru) | 2018-10-01 | 2021-06-25 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей |
| KR20210087458A (ko) | 2018-10-01 | 2021-07-12 | 아디셋 바이오, 인크. | 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법 |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3130442A1 (en) * | 2019-02-24 | 2020-08-27 | Gamida Cell Ltd. | Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy |
| KR20220017892A (ko) * | 2019-05-08 | 2022-02-14 | 얀센 바이오테크 인코포레이티드 | T세포 매개 면역의 조절을 위한 물질 및 방법 |
| WO2021016652A1 (en) * | 2019-07-29 | 2021-02-04 | The University Of Melbourne | METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| CN111647070B (zh) * | 2020-06-17 | 2022-06-03 | 深圳豪石生物科技有限公司 | T细胞受体或其抗原结合片段及应用 |
| IL300530A (en) * | 2020-08-12 | 2023-04-01 | Univ Central Florida Res Found Inc | Methods and preparations for stimulating GAMMA DELTA T cells |
| KR20240037892A (ko) | 2021-06-01 | 2024-03-22 | 트리움비라 이뮤놀로직스 유에스에이, 인크. | 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도 |
| WO2023069322A1 (en) * | 2021-10-20 | 2023-04-27 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
| EP4433068A4 (en) * | 2021-11-18 | 2025-11-12 | Univ Minnesota | LARGE-SCALE MULTIPLICATION OF MODIFIED HUMAN GAMMA T LYMPHOCYTES |
| EP4183871A1 (en) | 2021-11-23 | 2023-05-24 | Université d'Aix-Marseille | Process for preparing a composition comprising a combined cell population |
| JP2025506506A (ja) | 2022-02-16 | 2025-03-11 | プリオセラ エスエーエス | Ｓ１ｐ受容体モジュレーターと組み合わせたｃａｒ細胞を用いた処置方法 |
| JP2025511408A (ja) * | 2022-04-04 | 2025-04-15 | ガンマデルタ セラピューティクス リミティッド | 新規遺伝子アーマリング |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
| WO2025046256A1 (en) | 2023-08-31 | 2025-03-06 | Universite D'aix-Marseille | Process for preparing a composition comprising a combined cell population |
| CN118064364B (zh) * | 2024-04-19 | 2024-07-05 | 赛德特生物制药有限公司 | 一种γδT细胞的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL125884A0 (en) | 1996-03-04 | 1999-04-11 | Targeted Genetics Corp | Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes |
| CA2360046A1 (en) * | 1999-01-28 | 2000-08-03 | Lawrence S. Lamb, Jr. | In vitro activated gamma delta lymphocytes |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| ES2653570T3 (es) * | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| JP5543207B2 (ja) * | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| EP2311470B1 (en) * | 2008-07-01 | 2015-05-27 | Medinet Co., Ltd. | Method for simultaneous induction of ctl and gamma delta t cell |
| AU2009291595A1 (en) * | 2008-09-11 | 2010-03-18 | University Of Florida Research Foundation, Inc. | System and method for producing T cells |
| WO2012156958A2 (en) | 2011-05-19 | 2012-11-22 | Instituto De Medicina Molecular | Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof |
| US20120321666A1 (en) | 2011-05-23 | 2012-12-20 | Cooper Laurence J N | T cell therapy for b cell lymphoma |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
-
2014
- 2014-10-24 CA CA2926859A patent/CA2926859A1/en not_active Abandoned
- 2014-10-24 US US15/031,610 patent/US9907820B2/en active Active
- 2014-10-24 WO PCT/US2014/062191 patent/WO2015061694A2/en not_active Ceased
- 2014-10-24 JP JP2016525990A patent/JP2016539929A/ja active Pending
- 2014-10-24 CN CN201480063632.0A patent/CN105848484A/zh active Pending
- 2014-10-24 KR KR1020167012774A patent/KR20160068960A/ko not_active Ceased
- 2014-10-24 EP EP14854993.4A patent/EP3060059A4/en not_active Withdrawn
- 2014-10-24 AU AU2014339926A patent/AU2014339926B2/en active Active
-
2018
- 2018-01-16 US US15/872,354 patent/US20180200299A1/en not_active Abandoned
- 2018-04-30 AU AU2018202976A patent/AU2018202976B2/en active Active
-
2020
- 2020-12-18 US US17/127,627 patent/US20210187028A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539929A5 (enExample) | ||
| Daher et al. | CAR‐NK cells: the next wave of cellular therapy for cancer | |
| Shankar et al. | Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies | |
| Becker et al. | Selection and expansion of natural killer cells for NK cell-based immunotherapy | |
| Themeli et al. | New cell sources for T cell engineering and adoptive immunotherapy | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| Lawand et al. | Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications | |
| JP7002769B2 (ja) | ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム | |
| Ames et al. | Advantages and clinical applications of natural killer cells in cancer immunotherapy | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Bae et al. | Activation of NKT cells in an anti-PD-1–resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells | |
| Lim et al. | GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo | |
| Wang et al. | CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells | |
| Dianat‐Moghadam et al. | Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells | |
| CN107002039B (zh) | 使用t细胞用于培养自然杀伤细胞的方法 | |
| ES2877108T3 (es) | Activación de linfocitos infiltrantes de médula en condiciones hipóxicas alternantes con normóxicas | |
| Janelle et al. | T-cell dysfunction as a limitation of adoptive immunotherapy: current concepts and mitigation strategies | |
| JP2016509840A5 (enExample) | ||
| JP2018502114A5 (enExample) | ||
| EP3138905A1 (en) | Method for natural killer cell expansion | |
| Han et al. | The progress and prospects of immune cell therapy for the treatment of cancer | |
| JP2017533706A5 (enExample) | ||
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| CN113226340A (zh) | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 | |
| JP2021505604A5 (enExample) |